Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $3.21, $0.34 better than the analyst estimate of $2.87. Revenue for the quarter came in at $732.8 million versus the consensus estimate of $727.48 million.

For the full year 2022, the company anticipates non-GAAP currency-neutral revenue growth of approximately 1.0 to 2.0 percent and an estimated non-GAAP operating margin of approximately 19.0 percent. Management will discuss this outlook in greater detail on the fourth-quarter and full-year 2021 financial results conference call.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.